ANANDA Scientific Inc., a biotech pharma company, and the New York University (NYU) Grossman School of Medicine announced a second clinical trial to evaluate the effects of CBD in proprietary ANANDA’s delivery technology on test subjects who treat spinal pain with opioids. The Colorado-based company said initial studies show ANANDA’s Liquid Structure CBD application, licensed from Lyotropic Delivery Systems Ltd., Israel, can help to reduce opioid intake for patients who suffer such chronic pain. An Investigational New Drug application for Liquid Structure has been approved by the U.S. Food and Drug Administration. The trial is led by Stephen Ross, MD, Associate Professor of Psychiatry and Director, NYU Addictive Disorders and Experimental Therapeutics Research Laboratory. Funding for the trial is from the National Institute on Drug Abuse, with additional support from ANANDA Scientific.